Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Significant change in ZAP-70 expression during the course of chronic lymphocytic leukemia

V. Vroblova, F. Vrbacky, M. Hrudkova, K. Jankovicova, D. Schmitzova, J. Maly, J. Krejsek, L. Smolej,

. 2010 ; 84 (6) : 513-7. [pub] 20100209

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12025939

INTRODUCTION: It is widely accepted that expression of ZAP-70 in chronic lymphocytic leukemia (CLL) remains stable in time. However, data supporting this notion are surprisingly scarce. Therefore, we assessed expression of ZAP-70 in serial samples taken during the course of the disease. PATIENTS AND METHODS: We studied 44 patients with CLL diagnosed according to NCI-WG criteria (34 men, 10 women, median age 62, range, 36-81). A total of 104 samples were examined; all patients had at least two measurements. Median interval between the first and the second sample was 13 months (range, 2-36). ZAP-70 expression was detected by flow cytometry using phycoerythrin-conjugated monoclonal antibody clone 1E7.2 and negative isotype control. Twenty percent of positive cells were considered as the threshold of positivity. RESULTS: Significant change in ZAP-70 expression (i.e. from positivity to negativity and vice versa) was detected in 15/44 patients (34%). Interestingly, 7/8 patients whose ZAP-70 expression converted to positivity had unmutated IgVH genes. In addition, the conversion was accompanied by clinical progression or relapse in all but one patient. On the other hand, 5/7 patients with loss of ZAP-70 had stable clinical course. One patient became ZAP-70-negative during treatment with prednisone for autoimmune hemolytic anemia. CONCLUSIONS: In contrast to commonly accepted opinion, significant change in ZAP-70 expression in time was detected in a substantial proportion of our patients with CLL. While the conversion to ZAP-70 negativity was found predominantly in patients with stable disease, change to positivity was typical in patients with unmutated IgVH genes at the time of progression or relapse. Based on our pilot results, repeated assessment of ZAP-70 expression might be especially useful at the time of progression or relapse in patients who were initially ZAP-70-negative.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12025939
003      
CZ-PrNML
005      
20200227142611.0
007      
ta
008      
120817s2010 enk f 000 0#eng||
009      
AR
024    7_
$a 10.1111/j.1600-0609.2010.01425.x $2 doi
035    __
$a (PubMed)20132303
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vroblová, Vladimíra $7 xx0104044 $u Institute of Clinical Immunology and Allergology, Charles University in Prague, School of Medicine and University Hospital in Hradec Kralove, Czech Republic. vroblvla@fnhk.cz
245    10
$a Significant change in ZAP-70 expression during the course of chronic lymphocytic leukemia / $c V. Vroblova, F. Vrbacky, M. Hrudkova, K. Jankovicova, D. Schmitzova, J. Maly, J. Krejsek, L. Smolej,
520    9_
$a INTRODUCTION: It is widely accepted that expression of ZAP-70 in chronic lymphocytic leukemia (CLL) remains stable in time. However, data supporting this notion are surprisingly scarce. Therefore, we assessed expression of ZAP-70 in serial samples taken during the course of the disease. PATIENTS AND METHODS: We studied 44 patients with CLL diagnosed according to NCI-WG criteria (34 men, 10 women, median age 62, range, 36-81). A total of 104 samples were examined; all patients had at least two measurements. Median interval between the first and the second sample was 13 months (range, 2-36). ZAP-70 expression was detected by flow cytometry using phycoerythrin-conjugated monoclonal antibody clone 1E7.2 and negative isotype control. Twenty percent of positive cells were considered as the threshold of positivity. RESULTS: Significant change in ZAP-70 expression (i.e. from positivity to negativity and vice versa) was detected in 15/44 patients (34%). Interestingly, 7/8 patients whose ZAP-70 expression converted to positivity had unmutated IgVH genes. In addition, the conversion was accompanied by clinical progression or relapse in all but one patient. On the other hand, 5/7 patients with loss of ZAP-70 had stable clinical course. One patient became ZAP-70-negative during treatment with prednisone for autoimmune hemolytic anemia. CONCLUSIONS: In contrast to commonly accepted opinion, significant change in ZAP-70 expression in time was detected in a substantial proportion of our patients with CLL. While the conversion to ZAP-70 negativity was found predominantly in patients with stable disease, change to positivity was typical in patients with unmutated IgVH genes at the time of progression or relapse. Based on our pilot results, repeated assessment of ZAP-70 expression might be especially useful at the time of progression or relapse in patients who were initially ZAP-70-negative.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a geny pro těžké řetězce imunoglobulinů $7 D050438
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x enzymologie $x etiologie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a pilotní projekty $7 D010865
650    _2
$a recidiva $7 D012008
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a protein-tyrosinkináza ZAP-70 $x krev $7 D051746
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1#
$a Vrbacký, Filip. $7 xx0230451
700    1_
$a Motyčková, Monika $7 xx0241598
700    1_
$a Jankovičová, Karolína $7 stk2008428938
700    1_
$a Schmitzová, Daniela $7 xx0128892
700    1_
$a Malý, Jaroslav, $d 1946- $7 nlk19990073524
700    1_
$a Krejsek, Jan, $d 1958- $7 nlk19990073429
700    1_
$a Smolej, Lukáš $7 xx0101489
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 84, č. 6 (2010), s. 513-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20132303 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20200227143021 $b ABA008
999    __
$a ok $b bmc $g 947981 $s 783285
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 84 $c 6 $d 513-7 $e 20100209 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
LZP    __
$a Pubmed-20120817/10/03

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...